Contrave market share stabilizing
The third quarter was one of transition for both Orexigen and the Contrave franchise as Takeda stopped detailing the obesity drug in the United States and Orexigen took up the mantle. Contrave market share fell from 7% to 6% in wake of the announcement, but prescription data indicate it is stabilizing. Outside of the US, progress continues as the product has launched in South Korea and five countries in Central and Eastern Europe (CEE) with launches in another six CEE countries expected in Q416.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.